International Lipid Expert Panel Recommendations and RACING Trial

Author(s):

Key Takeaways

Pediatric lipid screening is vital for early dyslipidemia detection, reducing future cardiovascular disease risk.
Guidelines suggest universal screening at ages 9-11 and 17-21, with selective screening for at-risk children.
Implementation is inconsistent due to barriers like lack of awareness and time constraints in clinical settings.
Strategies to enhance uptake include routine integration, electronic health record reminders, and education for providers and families.

Panelists discuss how the International Lipid Expert Panel advocates for combination therapy as initial treatment in patients with elevated LDL-C and very high cardiovascular risk rather than sequential monotherapy.

EP: 1.Prevalence of Cardiovascular Disease

EP: 2.AHA Guidelines and Patient Mortality

EP: 3.Role of LDL-C in ASCVD

EP: 4.Pediatric Lipid Screening

EP: 5.Lp(a) in Pediatrics

EP: 6.DCRM Recommendations for Lipid Testing and LDL-C Management

EP: 7.Other Lipid Biomarkers

EP: 8.LDL-C Management in Subpopulations

EP: 9.Cost Considerations for LDL Reduction Therapies

EP: 10.Familial Hypercholesterolemia Testing

EP: 11.Role of Lp(a) in ASCVD Risk

EP: 12.Data Analysis: State of LDL-C Control in Patients With ASCVD

EP: 13.Pediatric Lipid Treatment Recommendations

Now Viewing

EP: 14.International Lipid Expert Panel Recommendations and RACING Trial

EP: 15.SPORT Trial

EP: 16.Novel Nonstatin LLTs for Lowering LDL-C and CVD Risk

EP: 17.CLEAR-Outcomes Data: Primary Prevention With Bempedoic Acid

EP: 18.Barriers Associated With Controlling LDL-C

EP: 19.Final Insights

Video content above is prompted by the following:

The International Lipid Expert Panel recommends combining therapies as a first-line treatment approach for patients who have elevated LDL-C and a very high risk for a cardiovascular event.